Component
Cisplatin-associated kaolin ingestion in rats
Experimental species, exposure and limitations are retained on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Gavage with 6-gingerol reduced kaolin ingestion after cisplatin administration in rats.
Experimental context and source evidence
- dose
- 6-Gingerol 50 or 100 mg/kg twice; cisplatin 6 mg/kg once, 1 h after first gingerol dose
- duration
- Gingerol at 07:00 and 19:00; assessment 24 h after cisplatin
- evidence_access
- Primary PubMed abstract.
- evidence_scope
- literature_reviewed; model-specific source-derived curation, not universally established human effects
- experimental_model
- Rats in a cisplatin-induced pica model
- limitations
- Rats do not vomit; pica is a surrogate. This experiment does not establish human antiemetic efficacy or preserved anticancer efficacy.
- nutrient_topic
- Gingerols collection; each molecular form and experimental preparation remains explicit. · Gingerols
- organism
- Rats in a cisplatin-induced pica model
- plain_language
- Gavage with 6-gingerol reduced kaolin ingestion after cisplatin administration in rats.
- primary_references
- [6]-Gingerol Ameliorates Cisplatin-Induced Pica by Regulating the TPH/MAO-A/SERT/5-HT/5-HT3 Receptor System in Rats. (2020). https://pubmed.ncbi.nlm.nih.gov/33061309/ DOI: 10.2147/DDDT.S270185
- route
- Gingerol gavage; cisplatin intraperitoneal injection
- tissue
- Kaolin intake, ileum, medulla oblongata and serum
Gingerols: mechanisms, molecular forms and cross-actor connections (2026-09-20) · lines 536–545
Original AI-assisted curation of thirteen primary research papers; study-specific PubMed/DOI links and limitations retained. Not publisher full text. · supports · Rats in a cisplatin-induced pica model · source_derived_draft · unverified_draft
## gingerols-6-cisplatin-pica Gavage with 6-gingerol reduced kaolin ingestion after cisplatin administration in rats. Model/species: Rats in a cisplatin-induced pica model Tissue: Kaolin intake, ileum, medulla oblongata and serum Exposure: 6-Gingerol 50 or 100 mg/kg twice; cisplatin 6 mg/kg once, 1 h after first gingerol dose Route: Gingerol gavage; cisplatin intraperitoneal injection Duration: Gingerol at 07:00 and 19:00; assessment 24 h after cisplatin Limits: Rats do not vomit; pica is a surrogate. This experiment does not establish human antiemetic efficacy or preserved anticancer efficacy. Primary reference: [6]-Gingerol Ameliorates Cisplatin-Induced Pica by Regulating the TPH/MAO-A/SERT/5-HT/5-HT3 Receptor System in Rats. (2020). https://pubmed.ncbi.nlm.nih.gov/33061309/ DOI: 10.2147/DDDT.S270185 Access: Primary PubMed abstract.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.